Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 58, Issue 7, 2003, Pages 595-601

  Jahnz Rozyk K ^a   Targowski, T ^a   Glodzinska Wyszogrodzka E ^a   Plusa T ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Allergen specific immunotherapy; Eotaxin; IgE mediated allergic rhinoconjunctivitis

Indexed keywords

ALLERGEN; ALLERGOVIT; BETA CHEMOKINE; BIOLOGICAL MARKER; EOTAXIN; IMMUNOGLOBULIN E;

ADULT; ALDER; ALLERGIC CONJUNCTIVITIS; ARTICLE; BIRCH; CEREAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GRASS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; POLLEN; PRIORITY JOURNAL; RHINOCONJUNCTIVITIS; SEASON; SERUM; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, INHALATION; ADULT; ALLERGENS; ANTI-ALLERGIC AGENTS; BETULA; BIOLOGICAL MARKERS; CEREALS; CHEMOKINES, CC; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; LORATADINE; MALE; POACEAE; POLAND; POLLEN; RHINITIS, ALLERGIC, SEASONAL; STATISTICS; TREATMENT OUTCOME;

EID: 18844463195     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2003.00083.x     Document Type: Article

References (24)

1. DURHAM SR, WALKER SM, VARGA EM, et al. Long-term clinical efficacy of grass pollen immunotherapy. New Engl J Med 1999;341:468-475.
2. HONDA K, CHIHARA J. Eosinophil activation by eotaxin - eotaxin primes the production of reactive oxygen species from eosinophils. J Allergy Clin Immunol 1999;54:1262-1269.
3. MORITA E, KAMEYOSHI Y, HIRAGUN T, MIHARA T, YAMAMOTO S. The C-C chemokines, RANTES and eotaxin, in atopic dermatitis. J Allergy Clin Immunol 2001;56:194-195.
4. JAHNZ-RÓŻYK K. Eotaxin - marker of allergic inflammation in asthma. Int Rev Allergol Clin Immunol 2000;6:5-10.
5. YAMADA H, YAMAGUCHI M, NAKAJIMA T, et al. Eotaxin in induced sputum of asthmatics: relationship with eosinophils and eosinophil cationic protein in sputum. J Allergy Clin Immunol 2000;55:392-397.
6. BROWN JR, KLEIMBERG J, MARINI M, SUN G, BELLINI A, MATTOLI S. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopses and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. Clin Exp Immunol 1998;114:137-146.
7. JOHANSSON SGO, O'B HOURIHANE J, BOUSQUET J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813-824.
8. MORITA A, SHIMOSAKO K, KIKUOKA S, et al. Development of a sensitive enzyme-linked immunosorbent assay for eotaxin and measurement of its levels in human blood. J Immunol Methods 1999;226:159-167.
9. GUEZ S, VATRINET C, FADEL R, ANDRE C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000;55:369-375.
10. ARIANO R, KROON AM, AUGERI G, CANONICA GW, PASSALACQUA G. Long-term treatment with allergoid immunotherapy to Parietaria. Clinical and immunologic effects in randomized, controlled trial. Allergy 1999;54:313-319.
11. JAHNZ-RÓŻYK K, TARGOWSKI T, GŁODZINSKA-WYSZOGRODZKA E, PŁUSA T. Eotaxin in IgE-mediated rhinoconjunctivitis. Allergy 2002;57:958-959.
12. JOSE PJ, GRIFFITHS-JOHNSON DA, COLLINS PD, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea-pig model of allergic airways inflamation. J Exp Med 1994;179:881-887.
13. ROTHENBERG ME, LUSTER AD, LILLY CM, DRAZEN JM, LEDER P. Constitutive and allergen-induced expression of eotaxin mRNA in the guinea-pig lung. J Exp Med 1995;181:1211-1216.
14. COLLINS PD, MARLEAU S, GRIFFITHS-JOHNSON DA, JOSE PJ, WILLIAMS TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995;182:1169-1174.
15. FUKUYAMA S, INOUE H, AIZAWA H, et al. Effect of eotaxin and platelet-activating factor on airway inflammation and hyperresponsiveness in guinea pigs in vivo. Am J Respir Crit Care Med 2000;161:1844-1849.
16. GREIFF L, PETERSON H, MATTSSON E, et al. Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment. Clin Exp Allergy 2001;31:1321-1327.
17. LILLY CM, NAKAMURA H, BELOSTOTSKY OJ, et al. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001;163:1669-1675.
18. TAHA RM, MINSHAL EM, MIOTTO D, et al. Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and non-asthmatic individuals. J Allergy Clin Immunol 1999;103:476-483.
19. HOSSNY E, ABOUL-MAGD M, BAKR S. Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children. Allergy 2001;56:996-1002.
20. LILLY CM, WOODRUFF PG, CAMARGO CA, et al. Elevated plasma eotaxin levels in patients with acute asthma. J Allergy Clin Immunol 1999;104:786-790.
21. WALSH GM. The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy 2000;55:53-61.
22. EDA R, SUGIYAMA H, HOPP RJ, BEWTRA AK, TOWNLEY RG. Effect of loratadine on human eosinophil function in vitro. Ann Allergy 1993;71:373-378.
23. CIPRANDI G, PRONZATO C, RICCA V, PASSALACQUA G, DANZING M, CANONICA ON. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy 1997;27:1175-1183.
24. BAROODY FM, LIM M, PROUD D, KAGEY-SOBOTKA A, LICHTENSTEIN LM, NACLERIO RM. Effects of loratadine and terfenadine on the induced nasal allergic reaction. Arch Otolaryngol Head Neck Surg 1996;122:309-316.